Diagnostic performance of third-generation sequencing for tuberculous pericarditis: a systematic review and meta-analysis protocol Authors: Guocan Yu, Yuyang Ling, Keying Du, Yanqin Shen Published: 2026 ABSTRACT Abstract AbstractIntroductionTuberculous pericarditis is a severe, high-mortality manifestation of extrapulmonary tuberculosis. Its diagnosis is hindered by the invasive nature of specimen collection and the limited sensitivity of conventional microbiological tests. Third-generation sequencing (TGS) offers a promising, rapid and comprehensive molecular approach for detecting Mycobacterium tuberculosis, but its specific diagnostic accuracy for tuberculous pericarditis has not been systematically evaluated. This planned systematic review and meta-analysis aims to precisely determine the diagnostic performance of TGS for this condition.Methods and analysisA protocol has been prospectively registered with PROSPERO. We will comprehensively search multiple databases (PubMed, Embase, Web of Science, SCOPUS, Cochrane Library) from inception to July 2027. We will include diagnostic accuracy studies that evaluate TGS against a composite reference standard for tuberculous pericarditis. Where available, we will also separately analyse studies that use a definitive reference standard. Two independent reviewers will screen records, extract data and assess methodological quality using the QUADAS-2 tool. A bivariate random-effects model will be used to pool sensitivity and specificity, with results summarised using hierarchical summary receiver operating characteristic curves. Heterogeneity will be explored via subgroup analysis and meta-regression. The certainty of evidence will be graded using the Grading of Recommendations Assessment, Development and Evaluation (GRADE) framework.Ethics and disseminationGiven that this investigation exclusively draws on open-source, non-identifiable data, formal institutional ethics clearance is not required. On finalisation, the findings of this systematic review will be disseminated via a suitable peer-reviewed journal. In parallel, every research phase—spanning protocol design to the final report—will rigorously comply with the established methodological standards for systematic reviews and meta-analyses of diagnostic test accuracy.Trial registration numberCRD420261429012.Keywords: Diagnostic microbiology, Molecular diagnostics, Tuberculosis STRENGTHS AND LIMITATIONS OF THIS STUDY The protocol underwent prospective registration and was developed following the Preferred Reporting Items for Systematic Review and Meta-Analysis Protocols (PRISMA-P) framework. The protocol underwent prospective registration and was developed following the Preferred Reporting Items for Systematic Review and Meta-Analysis Protocols (PRISMA-P) framework. The search strategies will encompass major international biomedical databases. The search strategies will encompass major international biomedical databases. Methodological robustness will be achieved through validated quality-assessment instruments and recognised approaches for synthesis and reporting. Methodological robustness will be achieved through validated quality-assessment instruments and recognised approaches for synthesis and reporting. One major limitation is the anticipated heterogeneity in both clinical and methodological aspects across eligible studies, potentially restricting the interpretability and generalisability of the combined accuracy results. One major limitation is the anticipated heterogeneity in both clinical and methodological aspects across eligible studies, potentially restricting the interpretability and generalisability of the combined accuracy results. Introduction Tuberculosis continues to pose a significant global health burden.1 Although pulmonary manifestations are most common, extra-pulmonary tuberculosis warrants serious attention due to its diagnostic complexity and potential severity.2 Tuberculous pericarditis is a critical form of extra-pulmonary tuberculosis, with a high mortality rate and a risk of progression to constrictive pericarditis, which can lead to chronic heart failure.3 Unlike conditions where specimens are readily accessible, obtaining diagnostic material for tuberculous pericarditis—through pericardiocentesis or pericardial biopsy—is an invasive procedure with inherent risks.4 This invasiveness contributes to the diagnostic challenge.5 Delayed or missed diagnosis can result in life-threatening complications such as cardiac tamponade or the long-term debilitating effects of constrictive pericarditis, severely impacting patient survival and quality of life.6 Conventional diagnostic methods using pericardial fluid, including smear microscopy, culture and molecular tests like Xpert MTB/RIF, often suffer from limited sensitivity due to the paucibacillary nature of the disease in this form.7 8 A previous meta-analysis indicated suboptimal accuracy for existing tests on pericardial specimens, highlighting the need for improved diagnostic approaches.9 Third-generation sequencing (TGS) technologies, such as nanopore and single-molecule real-time sequencing, offer a promising solution by enabling the rapid and comprehensive detection of Mycobacterium tuberculosis DNA and resistance markers directly from clinical samples.10–13 While TGS has shown enhanced diagnostic performance for various forms of tuberculosis,14–17 its specific accuracy for diagnosing tuberculous pericarditis using pericardial fluid or tissue samples has not been systematically evaluated. To address this evidence gap, we will conduct a systematic review and meta-analysis to precisely determine the diagnostic performance of TGS for tuberculous pericarditis. This study protocol has been formulated prior to the review to ensure a methodologically rigorous and transparent investigation. Methods and analysis Protocol development and registration A study protocol was designed and prospectively registered on PROSPERO (CRD420261429012) prior to commencement. This protocol was developed in adherence to the Preferred Reporting Items for Systematic Review and Meta-Analysis Protocols (PRISMA-P) guidelines.18 The completed meta-analysis will be reported in accordance with the Preferred Reporting Items for a Systematic Review and Meta-analysis of Diagnostic Test Accuracy Studies (PRISMA-DTA Statement,19 which provides specific guidance for systematic reviews and meta-analyses of diagnostic test accuracy studies. Since this work uses only publicly available data, obtaining institutional ethical approval is not necessary. Eligibility criteria Study selection will be conducted according to the PICT framework. Participants (P): The review will include studies enrolling patients with suspected tuberculous pericarditis, with no restrictions based on sex, age or ethnicity. Index test (I): The diagnostic performance of TGS will be evaluated as the index test. Comparator (C): A composite reference standard for tuberculous pericarditis will be applied. This standard will be categorised into two levels: Definitive reference standard: Microbiological confirmation (positive smear, culture or molecular test for MTB in pericardial fluid or tissue) and/or histopathological demonstration of caseating granulomas in pericardial tissue. Clinical diagnosis reference standard: In the absence of microbiological/histopathological confirmation, a diagnosis based on a combination of at least two of the following: (a) supportive imaging findings (pericardial effusion, thickening or enhancement on echocardiography or CT); (b) a positive tuberculosis immunological test (eg, interferon-gamma release assay (IGRA)); and (c) a definitive clinical response to antituberculosis therapy, as judged by the original study investigators. We will record which components were used in each included study. For studies that provide data for both categories, we will extract accuracy estimates separately when possible. For studies using only clinical diagnosis reference standard, we will note this as a potential source of heterogeneity and include them in the primary analysis but also perform a sensitivity analysis restricted to definitively confirmed cases. If a study reports both microbiological/histopathological and clinical data that are discordant, we will prioritise the microbiological/histopathological result for the definitive analysis, and we will describe the discordance and its potential impact in the discussion. Target condition (T): The condition of interest will be definitively diagnosed tuberculous pericarditis. Studies will be considered eligible if they provide, or permit the calculation of, sensitivity and specificity values for TGS against the aforementioned composite standard. Furthermore, sufficient data must be available to populate a 2×2 contingency table (true positives, false positives, false negatives, true negatives). Studies with incomplete but potentially obtainable data through direct contact with the original investigators will also be included for assessment. Exclusion criteria Studies will be excluded if they meet any of the following criteria: (1) insufficient data to populate a 2×2 contingency table (ie, true positives, false positives, false negatives, true negatives), even after attempting to contact the authors; (2) publication types limited to case reports, reviews, conference abstracts or meta-analyses; (3) unavailability of the full-text article. Information sources We will conduct a comprehensive literature search to identify eligible studies across multiple databases, including PubMed, Embase, Web of Science (SCIE), SCOPUS, the Cochrane Library (The Cochrane Database of Systematic Reviews and CENTRAL—Cochrane Central Register of Controlled Trials). The search of the literature will be carried out between 1 July 2027 and 31 July 2027. Extraction of data from eligible studies is anticipated to finish by 30 November 2027, while the final write-up of the results is planned for 31 March 2028. To supplement the electronic search, we will also manually screen the reference lists of all included articles and relevant systematic reviews to identify any additional studies that may have been missed. Search strategy Database-specific search strategies (online supplemental file 1) will be designed through collaboration between GY and YL, in consultation with an experienced research librarian affiliated with our institution who peer-reviewed the final search strategies. The search will not apply any language restrictions. A preliminary search strategy for PubMed is outlined below: #1 “Tuberculous pericarditis” OR “Pericardial tuberculosis” OR “TB pericarditis” OR “Tuberculosis pericarditis” OR “Tuberculous pericardial effusion” OR “Extrapulmonary Tuberculosis” OR “Extra pulmonary Tuberculosis” #2 “pericardial fluid” OR “pericardial effusion” OR “pericardial tissue” OR “pericardiocentesis” OR “pericardial biopsy” #3 #1 OR #2 #4 “Third-Generation Sequencing” OR “TGS” OR “Single-Molecule Real-Time Sequencing” OR “SMRT sequencing” OR “Oxford Nanopore Sequencing” OR “Nanopore sequencing” OR “Long-read sequencing” OR “PacBio sequencing” #5 #3 AND #4 Translation of non-English studies Since no language restrictions will be applied in the search, we have developed a structured plan for handling non-English records. During the title/abstract screening stage, any non-English record will be translated using online machine-translation tools (such as DeepL) to determine its potential relevance. If the record appears to meet the eligibility criteria, the full-text article will be obtained. For full-text articles, a comprehensive translation will be performed either by a professional translation service or by bilingual members of our research team who are fluent in the source language. Literature screening and selection The screening and selection of studies will be conducted by two independent investigators (GY and YL) following a three-stage process in line with PRISMA guidelines. First, after removing duplicate records using EndNote V.9.2 (Clarivate Analytics), the reviewers will screen titles to exclude clearly irrelevant publications. Second, the remaining records will undergo abstract review to assess their relevance to the study protocol. Finally, the full texts of potentially eligible studies will be retrieved and evaluated against the predefined inclusion and exclusion criteria. Any discrepancies between the reviewers will be resolved through consensus discussion or, if needed, by consulting a senior investigator (YS) for a final decision. Reasons for excluding studies at the full-text stage will be systematically recorded. Data extraction Following the final selection of studies, data will be independently extracted by two investigators (GY and YL) using a standardised, pre-piloted form. Discrepancies will be addressed through joint re-evaluation of the source document and, if consensus is not reached, by adjudication from a third reviewer (YS). The following data will be collected: Study characteristics: First author, publication year, country, study design and patient enrolment method (consecutive or non-consecutive). Patient profile: Total sample size, age distribution (paediatric/adult) and HIV or not. Diagnostic reference: Composite reference standard used for diagnosing tuberculous pericarditis, with explicit recording of which components (microbiology, histopathology, imaging, immunology and treatment response) were employed and whether the study allowed separate extraction of data for a definitive subset, along with details on specimen type (eg, pericardial fluid and tissue). TGS methodology: Specimen processing details (decontamination, homogenisation and fresh/frozen state); TGS approach (eg, metagenomic vs targeted); specific sequencing platform (eg, Oxford Nanopore or PacBio); and laboratory accreditation status. Performance data: Raw data necessary to construct 2×2 contingency tables (true positive, false positive, false negative and true negative counts) for calculating sensitivity and specificity. Quality evaluation The methodological quality of the included diagnostic accuracy studies will be assessed using the Quality Assessment of Diagnostic Accuracy Studies-2 (QUADAS-2) tool.20 Two reviewers will independently evaluate the risk of bias across four key domains: patient selection, index test (TGS), reference standard and patient flow/timing. Each domain will be judged as having a ‘low’, ‘high’ or ‘unclear’ risk of bias, supported by explicit justifications based on the study report. Any discrepancies in these assessments will be resolved through consensus discussion or, if needed, by arbitration from a third reviewer (YS). Publication bias In line with PRISMA-DTA guidance, a formal evaluation for publication bias will not be conducted.19 Established methods for detecting such bias in meta-analysis of diagnostic accuracy—for instance, examining funnel plot asymmetry—are considered to have questionable validity in this setting. This limitation stems primarily from the inherent heterogeneity in diagnostic thresholds and the variability in clinical spectrum among the included studies. Evidence evaluation The certainty of the evidence for the primary diagnostic outcomes will be assessed according to the Grading of Recommendations Assessment, Development and Evaluation (GRADE) framework. Using this approach, the overall evidence for each outcome will be categorised as high, moderate, low or very low certainty. This judgement will be based on a structured evaluation across five domains: risk of bias, inconsistency, indirectness, imprecision and publication bias. Data synthesis and statistical analysis Diagnostic accuracy will be assessed by calculating pooled estimates of sensitivity, specificity, positive and negative likelihood ratios (PLR, NLR) and diagnostic OR. The primary synthesis will be performed using a bivariate random-effects model to jointly model sensitivity and specificity, accounting for both within-study variability and between-study heterogeneity. The overall diagnostic performance will be summarised by the area under the hierarchical summary receiver operating characteristic (HSROC) curve (AUC). All results will be reported as point estimates with corresponding 95% CIs and presented using forest plots and HSROC curves. Statistical heterogeneity will be quantified using the inconsistency index (I²), interpreted as follows: ≤50% indicates moderate heterogeneity, and >50% indicates substantial heterogeneity. Where substantial heterogeneity is present (I²>50%), exploratory subgroup analysis and meta-regression will be conducted to investigate potential sources. To account for heterogeneity introduced by different reference standard definitions, we will perform the following pre-specified subgroup and sensitivity analyses: pre-specified covariates for these analyses include: study design (prospective vs retrospective) and patient enrolment method (consecutive vs convenience sampling). Clinical and host factors, such as age group (paediatric vs adult) and HIV serostatus. Specimen characteristics, including state (fresh vs frozen) and processing method. TGS methodology, encompassing the sequencing platform (eg, Oxford Nanopore or PacBio), sequencing approach (metagenomic vs targeted) and sequencing depth. Composite reference standard (definitive vs clinical diagnosis reference standard). Subgroup analysis by reference standard category: We will stratify studies according to whether they used a definitive (microbiological/histopathological) or a clinical diagnosis reference standard and we will compare pooled sensitivity and specificity between these groups. Sensitivity analysis restricted to definitive reference standard: We will re-run the bivariate model including only studies that used a microbiological or histopathological reference standard. This analysis will provide an estimate of TGS accuracy against the most rigorous reference available. We will also perform a leave-one-out analysis and, if sufficient data are available, a meta-regression with reference standard type as a covariate. All results from these analyses will be reported alongside the primary estimates and any differences will be discussed in the context of potential bias and clinical applicability. A leave-one-out sensitivity analysis will be performed by iteratively removing individual studies to evaluate their influence on the pooled estimates and overall heterogeneity. If four or more studies are included in a comparison, the bivariate and HSROC modelling will be performed using the specialised ‘midas’ and ‘metandi’ commands in STATA software (V.15.0, StataCorp LP). For analysis involving fewer than four studies, the analysis will use Meta-DiSc software (V.1.4), employing a fixed-effect model with exact binomial CIs to derive pooled estimates. Declarations Ethics and dissemination Given that this investigation exclusively draws on open-source, non-identifiable data, formal institutional ethics clearance is not required. On finalisation, the findings of this systematic review will be disseminated via a suitable peer-reviewed journal. In parallel, every research phase—spanning protocol design to the final report—will rigorously comply with the established methodological standards for systematic reviews and meta-analyses of diagnostic test accuracy. Supplementary material Acknowledgements We are grateful to the research teams whose studies were included in this meta‑analysis, particularly those who provided the detailed data needed for our quantitative synthesis. Our thanks also go to the patients whose clinical records underpin these studies; their contribution is essential to advancing the diagnosis of tuberculous pericarditis. We also sincerely thank the research librarian who provided expert guidance and peer review of our search strategies. Footnotes Funding: This work was supported by the Hangzhou Biomedicine and Health Industry Development Supporting Science and Technology Special Project. Guocan Yu, Yanqin Shen, 2023WJC162, 2023WJC312. The funder does not have a role in study design, data collection and analysis, decision to publish or preparation of the manuscript. Prepublication history and additional supplemental material for this paper are available online. To view these files, please visit the journal online (https://doi.org/10.1136/bmjopen-2026-124499). Provenance and peer review: Not commissioned; externally peer reviewed. Patient consent for publication: Not applicable. Patient and public involvement: Patients and/or the public were not involved in the design, or conduct, or reporting, or dissemination plans of this research. References Supplementary Materials